Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Localization of hRad9 in breast cancer

Authors: Vivian Chan, US Khoo, MS Wong, Ken Lau, Dacita Suen, George Li, Ava Kwong, TK Chan

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

hRad9 is a cell cycle checkpoint gene that is up-regulated in breast cancer. We have previously shown that the mRNA up-regulation correlated with tumor size and local recurrence. Immunohistochemical studies were made to better define the role of hRad9 in breast carcinogenesis.

Methods

Localisation of hRad9 protein were performed on paired tumor and normal breast tissues. Immunoblotting with and without dephosphorylation was used to define the protein isolated from breast cancer cells.

Results

Increased hRad9 protein was observed in breast cancer cells nucleus compared to non-tumor epithelium. This nuclear protein existed in hyperphosphorylated forms which may be those of the hRad9-hRad1-hHus1 complex.

Conclusion

Finding of hyperphosphorylated forms of hRad9 in the nucleus of cancer cells is in keeping with its function in ameliorating DNA instability, whereby it inadvertently assists tumor growth.
Appendix
Available only for authorised users
Literature
1.
Lieberman HB, Hopkins KM, Nass M, Demetrick D, Darvey S: A human homolog of the Schizosaccharomyces pombe rad9 + checkpoint control gene. Proc Natl Acad Sci USA. 1996, 93: 13890-13895. 10.1073/pnas.93.24.13890.CrossRefPubMedPubMedCentral
2.
Wang L, Hsu C-L, Ni J, Wang P-H, Yeh S, Keng P, Chang C: Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells. Mol Cell Biol. 2004, 24: 2202-2213. 10.1128/MCB.24.5.2202-2213.2004.CrossRefPubMedPubMedCentral
3.
Hopkins KM, Wang X, Berlin A, Hang H, Thaker HM, Lieberman HB: Expression of mammalian paralogues of HRAD9 and Mrad9 checkpoint control genes in normal and cancerous testicular tissue. Cancer Res. 2003, 63: 5291-5298.PubMed
4.
Paulovich AG, Toczyski DP, Hartwell LH: When checkpoints fail. Cell. 1997, 88: 315-321. 10.1016/S0092-8674(00)81870-X.CrossRefPubMed
5.
Hartwell LH, Kastan MB: Cell cycle control and cancer. Science. 1994, 266: 1821-1828. 10.1126/science.7997877.CrossRefPubMed
6.
Maniwa Y, Yoshimura M, Bermudez VP, Yuki T, Okada K, Kanomata N, Ohbayashi C, Hayashi Y, Hurwitz J, Okita Y: Accumulation of hRad9 protein in the nuclei of nonsmall cell lung carcinoma cells. Cancer. 2005, 103: 126-132. 10.1002/cncr.20740.CrossRefPubMed
7.
Maniwa Y, Yoshimura M, Bermudez VP, Okada K, Kanomata N, Ohbayashi C, Nishimura Y, Hayashi Y, Hurwitz J, Okita Y: His239Arg SNP of HRAD9 is associated with lung adenocarcinoma. Cancer. 2006, 106: 1117-1122. 10.1002/cncr.21705.CrossRefPubMed
8.
Cheng CK, Chow LW, Loo WT, Chan TK, Chan V: The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res. 2005, 65: 8646-8654. 10.1158/0008-5472.CAN-04-4243.CrossRefPubMed
9.
Volkmer E, Karnitz LM: Human homologs of Schizosaccharomyces pombe rad1, hus1, and rad9 form a DNA damage-responsive protein complex. J Biol Chem. 1999, 274: 567-570. 10.1074/jbc.274.2.567.CrossRefPubMed
10.
St Onge RP, Besley BDA, Pelley JL, Davey S: A role for the phosphorylation of hRad9 in checkpoint signaling. J Biol Chem. 2003, 278: 26620-26628. 10.1074/jbc.M303134200.CrossRefPubMed
11.
Hirari I, Wang HG: A role of the C-terminal region of human Rad9 (hRad9) in nuclear transport of the hRad9 checkpoint complex. J Biol Chem. 2002, 277: 25722-25727. 10.1074/jbc.M203079200.CrossRef
12.
13.
Komatsu K, Miyashita T, Hang H, Hopkins KM, Zheng W, Cuddeback S, Yamada M, Lieberman HB, Wang HG: Human homologue of S pombe Rad9 interacts with Bcl-2/Bcl-xL and promotes apoptosis. Nat Cell Biol. 2000, 2: 1-6. 10.1038/71316.CrossRefPubMed
14.
Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990, 335: 675-679. 10.1016/0140-6736(90)90801-B.CrossRefPubMed
15.
Lindsey-Boltz LA, Bermudez VP, Hurwitz J, Sancar A: Purification and characterization of human DNA damage checkpoint Rad complexes. Proc Natl Acad Sci U S A. 2001, 98: 11236-11241. 10.1073/pnas.201373498.CrossRefPubMedPubMedCentral
Metadata
Title
Localization of hRad9 in breast cancer
Authors
Vivian Chan
US Khoo
MS Wong
Ken Lau
Dacita Suen
George Li
Ava Kwong
TK Chan
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-196

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer

Research article

Clinicopathological significance of expression of p-c-Jun, TCF4 and beta-Catenin in colorectal tumors

Research article

Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer

Research article

The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions

Research article

Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer

Research article

Benchmarking the quality of breast cancer care in a nationwide voluntary system: the first five-year results (2003–2007) from Germany as a proof of concept
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits